Solvay shopping its drug business. Belgian conglomerate Solvay is eying an exit of the drug business with a sale of its pharmaceutical division that could be worth upwards of €5 billion, or $6.6 billion. Solvay didn’t go into details about why it might give up its fastest-growing and most profitable division. But after talk of a deal involving Solvay, the company issued a statement Wednesday saying it was exploring “various options for its pharmaceutical activities,” and that this review involves “discussions with third parties.”
Watson wins an important round with J&J on Concerta going generic.
Genzyme takes over rights to MS and Oncology drugs from Bayer HealthCare – Genzyme has scooped up key worldwide rights to the leukemia drug Campath–which is being studied as a treatment for MS–and two cancer therapies from its development partner Bayer HealthCare in a deal with a potential $2.8 billion payout.
——
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply